Newsroom | 49777 results
Sorted by: Latest
-
Aro Biotherapeutics Reports Preliminary Efficacy for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)
PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics Reports Preliminary Efficacy for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)...
-
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025. The Company is hosting a conference call today, February 5, 2026, at 4:30 p.m. ET to discuss the results. “We had another quarter of strong execution across all areas of our business and we think Arrowhead is extremely well positioned to build on this progress throughout 2026 and beyond,” said Christopher Anzalone, Ph.D.,...
-
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that data from two different analyses presented today at the 22nd Annual WORLDSymposium™ demonstrate that the long-term administration of tralesinidase alfa enzyme replacement therapy (TA-ERT) resulted in rapid and durable reduction of hepar...
-
Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the closing of its previously announced upsized initial public offering of 17,339,294 shares of its common stock at an initial public offering price of $17.00 per share, including 2,261,647 shares sold pursuant to the exerc...
-
Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
NEW ORLEANS--(BUSINESS WIRE)--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibitor asundexian (50mg) compared to placebo, both in combination with antiplatelet therapy. Asundexian significantly reduced ischemic stroke by 26% (csHR 0.74; 95% CI 0.65–0.84; p<.0001), in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase i...
-
Feinstein Institutes’ Dr. Stephanie Fitzpatrick elected Fellow of the Academy of Behavior Medicine Research
MANHASSET, N.Y.--(BUSINESS WIRE)--For her leadership in behavioral medicine and health equity, Stephanie L. Fitzpatrick, PhD, a clinical health psychologist, behavioral medicine researcher and implementation scientist at Northwell Health’s Feinstein Institutes for Medical Research, has been elected a Fellow of the Academy of Behavioral Medicine Research (ABMR), the premier honorary scientific organization in her field. The ABMR fellowship recognizes Dr. Fitzpatrick for her extensive contributio...
-
Magnus Medical Announces First Patient Enrolled at University of Massachusetts in Pivotal DoD-Funded Multisite Study of SAINT for Postpartum Depression
BURLINGAME, Calif.--(BUSINESS WIRE)--Magnus Medical, Inc., a pioneering therapeutic neuromodulation company advancing precision medicine in brain health, today announced enrollment of the first patient at University of Massachusetts Chan Medical School (UMass Chan), a leading academic health system, in its U.S. Department of Defense (DoD)-funded, multi-center pivotal clinical trial designed to evaluate the safety and effectiveness of SAINT® neuromodulation therapy for the treatment of postpartu...
-
Mirum Pharmaceuticals annonce l’homologation par Santé Canada de LIVMARLI® sous forme de comprimés pour le traitement du prurit cholestatique chez les patients atteints du syndrome d’Alagille
TORONTO--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq : MIRM), une entreprise à l’avant-garde dans le domaine des maladies rares, vient d’annoncer que Santé Canada a autorisé la mise en marché de LIVMARLI® (maralixibat) sous forme de comprimés pour le traitement du prurit cholestatique chez les patients atteints du syndrome d’Alagille. LIVMARLI était déjà approuvé au Canada sous forme de solution orale pour le traitement du prurit cholestatique chez les patients âgés de 12 mois ou plus...
-
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
TORONTO--(BUSINESS WIRE)--Mirum Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Alagille Syndrome...
-
Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation, alongside other recently introduced solutions spanning sample preparation,...
